Innovent Biologics Statistics
Total Valuation
IVBXF has a market cap or net worth of 10.56 billion. The enterprise value is 9.87 billion.
| Market Cap | 10.56B |
| Enterprise Value | 9.87B |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.65B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.35% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.53B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 187.14 |
| PS Ratio | 8.18 |
| PB Ratio | 5.87 |
| P/TBV Ratio | 6.01 |
| P/FCF Ratio | 239.74 |
| P/OCF Ratio | 59.86 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -761.01 |
| EV / Sales | 7.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 224.09 |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.35 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 50.93 |
| Debt / FCF | 8.81 |
| Interest Coverage | -4.09 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on invested capital (ROIC) is -1.08%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -0.82% |
| Return on Invested Capital (ROIC) | -1.08% |
| Return on Capital Employed (ROCE) | -1.60% |
| Revenue Per Employee | 228,102 |
| Profits Per Employee | -2,291 |
| Employee Count | 5,659 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.93% in the last 52 weeks. The beta is 0.28, so IVBXF's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +16.93% |
| 50-Day Moving Average | 5.80 |
| 200-Day Moving Average | 5.23 |
| Relative Strength Index (RSI) | 43.01 |
| Average Volume (20 Days) | 198 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IVBXF had revenue of 1.29 billion and -12.96 million in losses. Loss per share was -0.01.
| Revenue | 1.29B |
| Gross Profit | 960.41M |
| Operating Income | -37.89M |
| Pretax Income | -10.77M |
| Net Income | -12.96M |
| EBITDA | 3.29M |
| EBIT | -37.89M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1.08 billion in cash and 387.86 million in debt, giving a net cash position of 692.24 million.
| Cash & Cash Equivalents | 1.08B |
| Total Debt | 387.86M |
| Net Cash | 692.24M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.80B |
| Book Value Per Share | 1.10 |
| Working Capital | 808.86M |
Cash Flow
In the last 12 months, operating cash flow was 176.33 million and capital expenditures -132.30 million, giving a free cash flow of 44.03 million.
| Operating Cash Flow | 176.33M |
| Capital Expenditures | -132.30M |
| Free Cash Flow | 44.03M |
| FCF Per Share | n/a |
Margins
Gross margin is 74.40%, with operating and profit margins of -2.94% and -1.00%.
| Gross Margin | 74.40% |
| Operating Margin | -2.94% |
| Pretax Margin | -0.83% |
| Profit Margin | -1.00% |
| EBITDA Margin | 0.25% |
| EBIT Margin | -2.94% |
| FCF Margin | 3.41% |
Dividends & Yields
IVBXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.35% |
| Shareholder Yield | -4.35% |
| Earnings Yield | -0.12% |
| FCF Yield | 0.42% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IVBXF has an Altman Z-Score of 3.86.
| Altman Z-Score | 3.86 |
| Piotroski F-Score | n/a |